# Gefitinib

## Iressa 250mg

##### 臨採

| TAH Drug Code      | [OIRE](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OIRE)                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | IRESSA is indicated for first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients with EGFR-TK mutations. IRESSA is also indicated as a second-line treatment for lung adenocarcinoma patients who have previously received chemotherapy but still experience local progression or metastasis.                                                                                                                                      |
| Dosing             | 250 mg orally once daily with or without food.                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Contraindications  | Patients with known severe hypersensitivity to gefinitib or to any of the excipients of Iressa.                                                                                                                                                                                                                                                                                                                                                                              |
| Adverse Effects    | Diarrhoea, nausea, skin rash, dry skin, vomiting, anorexia, stomatitis, liver function abnormalities, nail disorder, alopecia, asthenia, conjunctivitis & blepharitis. Dermatologic: Acne (25% to 33% ), Dry skin (13% to 26% ), Pruritus (8% to 9% ), Rash (43% to 54% ) Endocrine metabolic: Weight loss (3% to 5% ) Gastrointestinal: Diarrhea (48% to 67% ), Loss of appetite (7% to 10% ), Nausea (13% to 18% ), Vomiting (9% to 12% ) Neurologic: Asthenia (4% to 6% ) |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Risk                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| More Info          | [UpToDate](https://www.uptodate.com/contents/gefitinib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                     |

